About Contact Us Careers

Immunotherapy Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 60
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Immunotherapy Drugs Landscape

Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Gilead Sciences, Inc.
Pfizer Inc.
AstraZeneca PLC
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
Bayer AG

Browse Key Market Insights with Data Illustration:

Immunotherapy Drugs Market Size & Share, Growth Trends 2037 [2025 Updated]

In the News

June 29, 2020: The United States Food and Drug Administration announced the approval of Keytruda (pembrolizumab), an immunotherapy (anti-PD-1 therapy) drug developed by Merck & Co., Inc., for the first-line treatment of mismatch repair deficient (dMMR) or unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer.

Author Credits: Radhika Pawar

Report ID: 60
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of immunotherapy drugs is estimated at USD 327.72 billion.

Immunotherapy Drugs Market size was valued at USD 290.22 billion in 2024 and is set to exceed USD 1.82 trillion by 2037, registering over 15.2% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, on the back of presence of several key players, along with growing number of new cancer cases registered every year in the region.

The major players in the market are Merck & Co., Inc., Gilead Sciences, Inc., Pfizer Inc., AstraZeneca PLC, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, and others.

Inquiry Before Buying Request Free Sample